Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. Holmer AK, et al. Among authors: vande casteele n. Therap Adv Gastroenterol. 2020 Nov 12;13:1756284820971214. doi: 10.1177/1756284820971214. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 33240396 Free PMC article.
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. Vande Casteele N, et al. Gut. 2015 Oct;64(10):1539-45. doi: 10.1136/gutjnl-2014-307883. Epub 2014 Oct 21. Gut. 2015. PMID: 25336114 Free PMC article. Clinical Trial.
IBD: Indication extrapolation for anti-TNF biosimilars.
Vande Casteele N, Sandborn WJ. Vande Casteele N, et al. Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):373-4. doi: 10.1038/nrgastro.2015.104. Epub 2015 Jun 16. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26077557
Efficient Early Drug Development for Ulcerative Colitis.
Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. Khanna R, et al. Among authors: vande casteele n. Gastroenterology. 2016 May;150(5):1056-1060. doi: 10.1053/j.gastro.2016.03.013. Epub 2016 Mar 24. Gastroenterology. 2016. PMID: 27018491 No abstract available.
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.
Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Melmed GY, et al. Among authors: vande casteele n. Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9. doi: 10.1016/j.cgh.2016.05.010. Epub 2016 May 14. Clin Gastroenterol Hepatol. 2016. PMID: 27189916
Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.
Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. Jairath V, et al. Among authors: vande casteele n. J Crohns Colitis. 2017 Feb;11(2):246-255. doi: 10.1093/ecco-jcc/jjw137. Epub 2016 Aug 3. J Crohns Colitis. 2017. PMID: 27487793 Review.
Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Hindryckx P, et al. Among authors: vande casteele n. Aliment Pharmacol Ther. 2017 Mar;45(5):617-630. doi: 10.1111/apt.13913. Epub 2017 Jan 11. Aliment Pharmacol Ther. 2017. PMID: 28074618 Free PMC article. Review.
144 results